SONIDEGIB
Manner of administration:Oral
Restriction
Indication: Metastatic or locally advanced basal cell carcinoma (BCC)
Treatment phase: Initial treatment
Restriction
Indication: Metastatic or locally advanced basal cell carcinoma (BCC)
Treatment phase: Continuing treatment
Restriction
Indication: Metastatic or locally advanced basal cell carcinoma (BCC)
Treatment phase: Initial treatment or Continuing treatment – balance of supply
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 3 | DPMQ: $7,593.29 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Odomzo | |||||